<tei>
    <teiHeader>
        <fileDesc xml:id="_Sato 2023.pdf"/>
    </teiHeader>
    <text xml:lang="en">


		<figure type="table">

            <note>TA B L E 1 </note>
 
            <figDesc>Patient baseline characteristics and univariate analysis<lb/> </figDesc>
<lb/> 
            <table>Variable<lb/> All patients<lb/> (n = 104)<lb/> Surgically<lb/> treated<lb/> (n = 48)<lb/> Unresectable<lb/> (n = 56)<lb/> p-value<lb/> Sex<lb/> Male/female<lb/> 68/36<lb/> 33/15<lb/> 35/21<lb/> 0.504<lb/> Age, years<lb/> Median (range)<lb/> 71 (36-86)<lb/> 71 (36-79)<lb/> 72 (36-86)<lb/> 0.825<lb/> ASA PS, class<lb/> 1/2/3<lb/> 52/33/19<lb/> 22/19/7<lb/> 30/14/12<lb/> 0.259<lb/> Time to diagnosis, days<lb/> Median (IQR)<lb/> 32 (11-65)<lb/> 36 (11-69)<lb/> 30 (11.5-60)<lb/> 0.724<lb/> Follow-up period, days<lb/> Median (IQR)<lb/> 509 (287-824)<lb/> 632 (444-1025)<lb/> 406 (137-572.5)<lb/> &lt;0.0001<lb/> Bismuth-Corlette type<lb/> I/II/IIIa/IIIb/IV<lb/> 15/11/44/15/19<lb/> 3/8/19/10/8<lb/> 12/3/25/5/11<lb/> 0.317<lb/> Clinical stage<lb/> I/II/IIIa/IIIb/IVa/IVb<lb/> 1/11/21/15/25/31<lb/> 1/8/13/12/14/0<lb/> 0/3/8/3/11/31<lb/> &lt;0.0001<lb/> Clinical T<lb/> T1a/T1b/T2a/T2b/T3/<lb/> T4a/T4bT1a/T1b/T2a/T2b/T3/T4a/T4b<lb/> 0/1/10/10/42/9/32<lb/> 0/1/6/7/21/3/10<lb/> 0/0/4/3/21/6/22<lb/> 0.009<lb/> Clinical N<lb/> N0/N1<lb/> 65/40<lb/> 16/32<lb/> 23/33<lb/> 0.415<lb/> Clinical M<lb/> M0/M1<lb/> 74/30<lb/> 48/0<lb/> 26/30<lb/> &lt;0.0001<lb/> AST, IU/L<lb/> Median (range)<lb/> 95 (18-969)<lb/> 112 (22-969)<lb/> 83 (18-674)<lb/> 0.487<lb/> ALT, IU/L<lb/> Median (range)<lb/> 156 (7-1080)<lb/> 177 (15-766)<lb/> 122 (7-1080)<lb/> 0.249<lb/> ALP, IU/L<lb/> Median (range)<lb/> 972 (277-4485)<lb/> 998 (308-2717)<lb/> 841 (277-4485)<lb/> 0.469<lb/> GGT, IU/L<lb/> Median (range)<lb/> 684 (20-3473)<lb/> 724 (136-1962)<lb/> 594 (20-3473)<lb/> 0.157<lb/> T-Bil, mg/dl<lb/> Median (range)<lb/> 4.8 (0.3-25.2)<lb/> 2.70 (0.5-21.5)<lb/> 5.68 (0.3-25.2)<lb/> 0.184<lb/> Prediagnostic<lb/> cholangitis<lb/> Yes/no<lb/> 31/73<lb/> 8/40<lb/> 23/33<lb/> 0.007<lb/> First drainage method †<lb/> ENBD/PS/inside<lb/> stent/PTBD/incomplete<lb/> study/no data<lb/> 61/31/2/3/6/1<lb/> 30/9/1/3/4/1<lb/> 31/22/1/0/2/0<lb/> 0.088<lb/> First drainage<lb/> segments<lb/> 0/1/2/3/no data<lb/> 6/86/11/0/1<lb/> 4/39/4/0/1<lb/> 2/47/7/0<lb/> 0.572<lb/> EST (including<lb/> previous)<lb/> Yes/no<lb/> 41/63<lb/> 18/30<lb/> 23/33<lb/> 0.710<lb/> Successful biliary<lb/> drainage (within 2<lb/> weeks)<lb/> Yes/no/no data<lb/> 74/27/3<lb/> 36/10/2<lb/> 38/17/1<lb/> 0.300<lb/> Successful biliary<lb/> drainage (no time<lb/> limit)<lb/> Yes/no<lb/> 103/1<lb/> 48/0<lb/> 55/1<lb/> 0.352<lb/> Diagnostic period, days<lb/> Median (IQR)<lb/> 23 (8-55)<lb/> 17 (6-32)<lb/> 33 (14-67)<lb/> 0.007<lb/> No of ERCP/PTBD<lb/> within diagnostic<lb/> period<lb/> Median( range)<lb/> 3 (1-13)<lb/> 2.5 (1-13)<lb/> 3 (1-12)<lb/> 0.031<lb/> Drainage-related<lb/> cholangitis<lb/> Yes/no<lb/> 52/52<lb/> 19/29<lb/> 33/23<lb/> 0.049<lb/> Final drainage method †<lb/> ENBD/PS/inside<lb/> stent/EMS/PTBD/<lb/> no stent<lb/> 4/58/17/6/12/7<lb/> 3/22/12/0/7/4<lb/> 1/36/5/6/5/3<lb/> 0.022<lb/> Final drainage<lb/> segments<lb/> 0/1/2/3<lb/> 7/65/28/4<lb/> 4/32/11/1<lb/> 3/33/17/3<lb/> 0.196<lb/> Post-ERCP pancreatitis<lb/> No pancreatitis/mild/<lb/> moderate/<lb/> severe/no data<lb/> 86/1/11/4/2<lb/> 41/0/4/3/0<lb/> 45/1/7/1/2<lb/> 0.627<lb/> </table>
<lb/> 
            <note>ASA-PS, American Society of Anesthesiologists physical status; IQR, interquartile range; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phos-<lb/>phatase; GGT, gamma-glutamyltransferase; T-Bil, total bilirubin; ENBD, endoscopic nasobiliary drainage; PS, plastic stent deployed transpapillary; PTBD, percutaneous<lb/> transhepatic biliary drainage; EST, endoscopic sphincterotomy; ERCP, endoscopic retrograde cholangiopancreatography; No., number; EMS, expandable metallic stent.<lb/> ΠComparisons of surgical patients and unresectable patients are shown as p-values.<lb/> <note>† ENBD+X→ENBD, PTBD+X→PTBD, PS+inside→PS</note>
		</figure>


		<figure type="table">

            <note>TA B L E 2 </note>
 
            <figDesc>Prognostic factors for all perihilar cholangiocarcinoma patients<lb/> </figDesc>
<lb/> 
            <table>Univariate analysis<lb/> Multivariate analysis<lb/> Variable<lb/> n<lb/> HR<lb/> 95% CI<lb/> p-value<lb/> HR<lb/> 95% CI<lb/> p-value<lb/> Sex<lb/> Male<lb/> 68<lb/> 0.79<lb/> 0.473-1.334 0.384<lb/> Female<lb/> 36<lb/> 1<lb/> Age<lb/> ≥75years<lb/> 41<lb/> 1.2<lb/> 0.733-1.974 0.465<lb/> &lt;75years<lb/> 63<lb/> 1<lb/> Surgical resection<lb/> Yes<lb/> 48<lb/> 0.41<lb/> 0.244-0.680 0.001<lb/> 0.44<lb/> 0.253-0.772<lb/> 0.004<lb/> No<lb/> 56<lb/> 1<lb/> 1<lb/> ASA-PS<lb/> Class 2-3<lb/> 51<lb/> 0.79<lb/> 0.485-1.302 0.362<lb/> Class 0-1<lb/> 53<lb/> 1<lb/> Bismuth type<lb/> IIIa+IV<lb/> 42<lb/> 1.80<lb/> 1.077-3.025 0.025<lb/> 1.86<lb/> 1.091-3.174<lb/> 0.023<lb/> I+II+IIIb<lb/> 62<lb/> 1<lb/> 1<lb/> EST (including previous)<lb/> Yes<lb/> 41<lb/> 1.68<lb/> 0.359-0.986 0.044<lb/> 1.61<lb/> 0.901-2.894<lb/> 0.108<lb/> No<lb/> 63<lb/> 1<lb/> 1<lb/> Prediagnostic cholangitis<lb/> Yes<lb/> 31<lb/> 0.96<lb/> 0.564-1.649 0.895<lb/> No<lb/> 73<lb/> 1<lb/> Drainage-related cholangitis<lb/> Yes<lb/> 52<lb/> 2.61<lb/> 1.556-4.385 0.0003<lb/> 2.44<lb/> 1.416-4.215<lb/> 0.001<lb/> No<lb/> 52<lb/> 1<lb/> 1<lb/> First drainage segments #<lb/> 2-3 segments<lb/> 11<lb/> 1,47<lb/> 0.629-3.455 0.371<lb/> 1 segment<lb/> 86<lb/> 1<lb/> Final drainage segments #<lb/> 2-3 segments<lb/> 32<lb/> 1.43<lb/> 0.844-2.407 0.185<lb/> 1 segment<lb/> 65<lb/> 1<lb/> Type of first drainage #<lb/> ENBD<lb/> 61<lb/> 0.78<lb/> 0.463-1.330 0.368<lb/> Not ENBD<lb/> 36<lb/> 1<lb/> No. of ERCP/PTBD sessions<lb/> within diagnostic period<lb/> 4 times or more<lb/> 32<lb/> 1.61<lb/> 0.953-2.711 0.075<lb/> 1-3 times<lb/> 72<lb/> 1<lb/> PTBD as final drainage<lb/> PTBD<lb/> 12<lb/> 1.86<lb/> 0.942-3.659 0.074<lb/> Not PTBD<lb/> 92<lb/> 1<lb/> T-Bil #<lb/> &gt;3 mg/dl<lb/> 57<lb/> 2.06<lb/> 1.201-3.540 0.009<lb/> 1.48<lb/> 0.825-2.671<lb/> 0.187<lb/> &lt;3 mg/dl<lb/> 41<lb/> 1<lb/> 1<lb/> ALP #<lb/> &gt;1800 IU/L<lb/> 28<lb/> 0.69<lb/> 0.366-1.308 0.257<lb/> &lt;1800 IU/L<lb/> 67<lb/> 1<lb/> GGT #<lb/> &gt;200 IU/L<lb/> 83<lb/> 0.77<lb/> 0.373-1.577 0.470<lb/> &lt;200 IU/L<lb/> 11<lb/> 1<lb/> </table>
<lb/> 
            <note>HR, hazard ratio; CI, confidence interval; ASA-PS, American Society of Anesthesiologists Physical Status; EST, endoscopic sphincterotomy; ENBD, endoscopic naso-<lb/>biliary drainage; No., number; ERCP, endoscopic retrograde cholangiopancreatography; PTBD, percutaneous transhepatic biliary drainage; T-Bil, total bilirubin; ALP,<lb/> alkaline phosphatase; GGT, gamma-glutamyltransferase.</note>
		</figure>


		<figure type="table">

            <note>TA B L E 3 </note>
 
            <figDesc>Prognostic factors for surgically treated perihilar cholangiocarcinoma patients<lb/> </figDesc>
<lb/> 
            <table>Univariate analysis<lb/> Multivariate analysis<lb/> Variable<lb/> n<lb/> HR<lb/> 95% CI<lb/> p-value<lb/> HR<lb/> 95% CI<lb/> p-value<lb/> Sex<lb/> Male<lb/> 33<lb/> 1.15<lb/> 0.502-2.622<lb/> 0.746<lb/> Female<lb/> 15<lb/> 1<lb/> Age<lb/> ≥75 years<lb/> 20<lb/> 1.42<lb/> 0.685-2.962<lb/> 0.344<lb/> &lt;75 years<lb/> 28<lb/> 1<lb/> Preoperative<lb/> chemotherapy<lb/> Yes<lb/> 7<lb/> 1.64<lb/> 0.563-4.761<lb/> 0.365<lb/> No<lb/> 41<lb/> 1<lb/> ASA-PS<lb/> Class 2-3<lb/> 26<lb/> 0.87<lb/> 0.419-1.826<lb/> 0.721<lb/> Class 0-1<lb/> 22<lb/> 1<lb/> T-Bil #<lb/> ≥3 mg/dl<lb/> 22<lb/> 2.05<lb/> 0.938-4.498<lb/> 0.072<lb/> &lt;3 mg/dl<lb/> 23<lb/> 1<lb/> Bismuth type<lb/> IIIa+IV<lb/> 27<lb/> 1.75<lb/> 0.825-3.709<lb/> 0.144<lb/> I+II+IIIb<lb/> 21<lb/> 1<lb/> EST(including<lb/> previous)<lb/> Yes<lb/> 18<lb/> 1.99<lb/> 0.912-4.333<lb/> 0.084<lb/> No<lb/> 30<lb/> 1<lb/> Pre-diagnostic<lb/> cholangitis<lb/> Yes<lb/> 8<lb/> 0.53<lb/> 0.201-1.410<lb/> 0.205<lb/> No<lb/> 40<lb/> 1<lb/> Drainage-related<lb/> cholangitis<lb/> Yes<lb/> 19<lb/> 3.78<lb/> 1.711-8.340<lb/> 0.001<lb/> 4.69<lb/> 1.671-13.142<lb/> 0.003<lb/> No<lb/> 29<lb/> 1<lb/> 1<lb/> First drainage<lb/> segments #<lb/> 2-3 segments<lb/> 4<lb/> 2.00<lb/> 0.441-9.044<lb/> 0.370<lb/> 1 segment<lb/> 39<lb/> 1<lb/> Final drainage<lb/> segments #<lb/> 2-3 segments<lb/> 12<lb/> 1.86<lb/> 0.823-4.203<lb/> 0.136<lb/> 1 segment<lb/> 32<lb/> 1<lb/> Type of first drainage #<lb/> ENBD<lb/> 30<lb/> 0.32<lb/> 0.134-0.746<lb/> 0.009<lb/> 0.51<lb/> 0.203-1.289<lb/> 0.155<lb/> Not ENBD<lb/> 13<lb/> 1<lb/> 1<lb/> No. of ERCP/PTBD<lb/> sessions within<lb/> diagnostic period<lb/> four times or<lb/> more<lb/> 9<lb/> 2.19<lb/> 0.886-5.398<lb/> 0.090<lb/> 1-3 times<lb/> 39<lb/> 1<lb/> PTBD as final drainage<lb/> PTBD<lb/> 7<lb/> 1.86<lb/> 0.751-4.604<lb/> 0.180<lb/> Not PTBD<lb/> 41<lb/> 1<lb/> </table>
<lb/> 
            <note>HR, hazard ratio; CI, confidence interval; ASA-PS, American Society of Anesthesiologists Physical Status;T-Bil, total bilirubin; EST, endoscopic sphincterotomy; ENBD,<lb/> endoscopic nasobiliary drainage; No., Number; ERCP, endoscopic retrograde cholangiopancreatography; PTBD, percutaneous transhepatic biliary drainage. <note># Patients<lb/> without data or with no stents were excluded.</note>
		</figure>


		<figure type="table">

            <head>TA B L E 4 </head>
 
            <figDesc>Risk factors for drainage-related cholangitis in surgically treated perihilar cholangiocarcinoma patients<lb/> </figDesc>
<lb/> 
            <table>Univariate analysis<lb/> Multivariate analysis<lb/> Variable<lb/> n<lb/> OR<lb/> 95% CI<lb/> p-value<lb/> OR<lb/> 95% CI<lb/> p-value<lb/> Sex<lb/> Male<lb/> 33<lb/> 0.98<lb/> 0.280-3.392<lb/> 0.968<lb/> Female<lb/> 15<lb/> 1<lb/> Age<lb/> ≥75 years<lb/> 20<lb/> 1.03<lb/> 0.319-3.329<lb/> 0.960<lb/> &lt;75 years<lb/> 28<lb/> 1<lb/> Preoperative<lb/> Chemotherapy<lb/> Yes<lb/> 7<lb/> 0.43<lb/> 0.085-2.200<lb/> 0.313<lb/> No<lb/> 41<lb/> 1<lb/> ASA-PS<lb/> Class 2-3<lb/> 26<lb/> 2.67<lb/> 0.793-8.969<lb/> 0.113<lb/> Class 0-1<lb/> 22<lb/> 1<lb/> T-Bil #<lb/> ≥3 mg/dl<lb/> 22<lb/> 1.90<lb/> 0.155-1.781<lb/> 0.301<lb/> &lt;3 mg/dl<lb/> 23<lb/> 1<lb/> Bismuth type<lb/> IIIa+IV<lb/> 27<lb/> 2.32<lb/> 0.692-7.792<lb/> 0.173<lb/> I+II+IIIb<lb/> 21<lb/> 1<lb/> EST(including<lb/> previous)<lb/> Yes<lb/> 18<lb/> 4.32<lb/> 1.243-15.024 0.021<lb/> 5.97<lb/> 1.070-33.377<lb/> 0.042<lb/> No<lb/> 30<lb/> 1<lb/> 1<lb/> Prediagnostic<lb/> cholangitis<lb/> Yes<lb/> 8<lb/> 1.67<lb/> 0.362-7.671<lb/> 0.512<lb/> No<lb/> 40<lb/> 1<lb/> First drainage<lb/> segments #<lb/> 2-3 segments<lb/> 4<lb/> 1.60<lb/> 0.203-12.596 0.655<lb/> 1 segment<lb/> 39<lb/> 1<lb/> Type of first drainage #<lb/> ENBD<lb/> 30<lb/> 0.16<lb/> 0.039-0.675<lb/> 0.012<lb/> 0.17<lb/> 0.0280-0.979<lb/> 0.047<lb/> Not ENBD<lb/> 13<lb/> 1<lb/> 1<lb/> No. of ERCP/PTBD<lb/> sessions within<lb/> diagnostic period<lb/> 4 times or more<lb/> 9<lb/> 7.88<lb/> 1.421-43.630 0.018<lb/> 36.30<lb/> 2.737-482.024<lb/> 0.007<lb/> 1-3 times<lb/> 39<lb/> 1<lb/> 1<lb/> </table>
<lb/> 
            <note>OR, odds ratio; CI, confidence interval; ASA-PS, American Society of Anesthesiologists Physical Status;T-Bil, total bilirubin; EST, endoscopic sphincterotomy; ENBD,<lb/> endoscopic nasobiliary drainage; No., number; ERCP, endoscopic retrograde cholangiopancreatography; PTBD, percutaneous transhepatic biliary drainage. <note># Patients<lb/> without data or with no stents were excluded<lb/> TA B L E 5 Pathological features of patients with or without drainage-related cholangitis<lb/> Drainage-</note>

            <head>related cholangitis<lb/> Variable<lb/> Yes (n = 19)<lb/> No (n = 29)<lb/> p-value<lb/> </head>
<lb/> 
            <table>Preoperative<lb/> chemotherapy $<lb/> Yes/no<lb/> 4 (1)/15<lb/> 3 (2)/26<lb/> 0.304<lb/> R0 resection<lb/> Yes/no<lb/> 17/2<lb/> 27/2<lb/> 0.656<lb/> Histology<lb/> Pap/tub/por<lb/> 0/19/0<lb/> 2/23/4<lb/> 0.106<lb/> Stroma<lb/> Med/int/sci<lb/> 0/17/2<lb/> 1/20/8<lb/> 0.236<lb/> Invasion type<lb/> INFa/INFb/INFc<lb/> 0/17/3<lb/> 1/18/10<lb/> 0.214<lb/> Lymphatic vessel<lb/> invasion<lb/> ly0/ly1/ly2<lb/> 10/8/1<lb/> 12/16/1<lb/> 0.519<lb/> Vascular invasion<lb/> v0/v1/v2<lb/> 13/6/0<lb/> 19/8/2<lb/> 0.720<lb/> Neural invasion<lb/> ne0/ne1/ne2/ne3<lb/> 2/3/7/7<lb/> 3/6/11/9<lb/> 0.682<lb/> pT<lb/> pT1a/pT2a/pT2b/pT3/pT4a/pT4b<lb/> 0/1/3/10/3/0/3<lb/> 0/1/7/15/6/0/0<lb/> 0.217<lb/> pN<lb/> pN0/pN1<lb/> 5/14<lb/> 19/10<lb/> 0.008<lb/> Adjuvant chemotherapy<lb/> Yes/no<lb/> 3/16<lb/> 5/24<lb/> 0.895<lb/> Postoperative<lb/> recurrence #<lb/> Yes/no<lb/> 12/5<lb/> 15/12<lb/> 0.319<lb/> </table>
<lb/> 
            <note>pap, papillary adenocarcinoma; tub, tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; med, medullary type; int, intermediate type; sci, scirrhous type;<lb/> INF, infiltration<lb/> <note>$ patients with neoadjuvant chemotherapy are shown in parenthesis.<lb/> <note># patients without R0 resection are excluded.</note>
		</figure>



    </text>
</tei>

